Shoulder ArthroscopyCCSS-MgNCT07798115
Magnesium Sulfate With Standard Combined Costoclavicular-Suprascapular Block for Pain Relief After Shoulder Arthroscopy.
A study testing Bupivacaine, Magnesium sulfate (MgSO4) and Normal Saline (NS) in people with Shoulder Arthroscopy and Postoperative Pain, run by Assiut University at 1 site in Egypt.
Trial summary
This study aims to evaluate whether adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block improves postoperative pain control in patients undergoing shoulder arthroscopy. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Shoulder Arthroscopy, Postoperative Pain, Regional Anesthesia
- What is being tested?
- Bupivacaine, Magnesium sulfate (MgSO4) and Normal Saline (NS)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2026to 30 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age between 18-50 years
- American Society of Anesthesiologists (ASA) physical status I-II.
- Scheduled for elective outpatient shoulder arthroscopy.
- Ability to understand the study protocol and use the NRS scale.
Who cannot join
- Refusal to participate.
- Known allergy or hypersensitivity to local anesthetics or magnesium sulphate.
- Coagulopathy or anticoagulant therapy contraindicating regional anesthesia.
- Local infection at the block site.
- Pre-existing peripheral neuropathy or neurologic deficit involving the operative limb.
- Body mass index (BMI) > 40 kg/m² (if desired for technical standardization).
Show all 9Show fewer
- Chronic opioid use or chronic pain syndrome affecting pain assessment.
- Pregnancy or lactation.
- Inability to communicate or complete postoperative assessments.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Assiut University Hospital
Asyut
Ahmed Shaban Abd Elbadea Khalifa, Assistant Lecturer, +20 1143990130, ahmedshabann144@gmail.com
Mohamed Talaat Mohamed, Lecturer, +20 1062012031, tal3t200895@aun.edu.eg
About this study
Official title: Analgesic Effect of Additional Magnesium Sulfate to Standard Combined Costoclavicular-suprascapular Block in Shoulder Arthroscopy.
This study aims to evaluate whether adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block improves postoperative pain control in patients undergoing shoulder arthroscopy. The study will compare pain management outcomes between patients receiving the nerve block with magnesium sulfate and those receiving the nerve block without magnesium sulfate. The main outcome will be the time to first rescue analgesia after surgery.
Read the detailed description
This randomized clinical trial will evaluate the analgesic effect of adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block in patients undergoing shoulder arthroscopy. Shoulder arthroscopy can be associated with significant postoperative pain, and effective regional anesthesia may improve postoperative analgesia and reduce the need for rescue analgesics.
Eligible patients undergoing shoulder arthroscopy will be randomly assigned to receive either a combined costoclavicular and suprascapular nerve block with magnesium sulfate as an adjuvant or the same nerve block without magnesium sulfate. Standardized anesthetic and postoperative analgesic protocols will be applied to both groups.
The primary outcome will be the time to first rescue analgesia after surgery. Secondary outcomes will include postoperative pain scores and other relevant analgesic and safety outcomes during the postoperative observation period.
The study aims to determine whether the addition of magnesium sulfate can prolong the duration of analgesia and improve postoperative pain management following shoulder arthroscopy.
- Being tested
- Bupivacaine, Magnesium sulfate (MgSO4), Normal Saline (NS), Costoclavicular Nerve Block, suprascapular nerve block
- Keywords
- Costoclavicular Block, Suprascapular Block, Magnesium Sulfate, Postoperative Pain, Shoulder Arthroscopy, Rescue Analgesia
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BupivacaineDrug
"Bupivacaine 0.5% will be used as the local anesthetic for ultrasound-guided costoclavicular and suprascapular nerve blocks. A total of 25 mg (5 mL) will be administered for the costoclavicular nerve block and 50 mg (10 mL) for the suprascapular nerve block, for a total dose of 75 mg per participant."
Magnesium sulfate (MgSO4)Drug
"Magnesium sulfate 150 mg (1.5 mL) will be used as an adjuvant to bupivacaine in each ultrasound-guided nerve block. A total of 300 mg (3 mL) of magnesium sulfate will be administered per participant, with 150 mg added to the costoclavicular nerve block and 150 mg added to the suprascapular nerve block."
Normal Saline (NS)Drug
"Normal saline (0.9% sodium chloride) will be used as the control adjuvant, with 1.5 mL added to the local anesthetic solution for the costoclavicular nerve block and 1.5 mL added to the local anesthetic solution for the suprascapular nerve block, for a total volume of 3 mL per participant."
Costoclavicular Nerve BlockProcedure or surgery
"A single-shot ultrasound-guided costoclavicular nerve block will be performed using 5 mL of 0.5% bupivacaine (25 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group."
suprascapular nerve blockProcedure or surgery
"A single-shot ultrasound-guided suprascapular nerve block will be performed using 10 mL of 0.5% bupivacaine (50 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group."
| Study group | Role | What they receive |
|---|---|---|
| Costoclavicular-Suprascapular Block with Normal Saline | Experimental | Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline. Receives: Drug: Bupivacaine; Drug: Normal Saline (NS); Procedure: Costoclavicular Nerve Block; Procedure: suprascapular nerve block |
| Costoclavicular-Suprascapular Block with regional Magnesium Sulfate | Experimental | Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of magnesium sulfate (150 mg), followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of magnesium sulfate (150 mg). Receives: Drug: Bupivacaine; Drug: Magnesium sulfate (MgSO4); Procedure: Costoclavicular Nerve Block; Procedure: suprascapular nerve block |
| Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate | Experimental | Participants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline. Following the nerve blocks, participants will receive 150 mg of magnesium sulfate diluted in 100 mL of 0.9% normal saline administered intravenously. Receives: Drug: Bupivacaine; Drug: Magnesium sulfate (MgSO4); Drug: Normal Saline (NS); Procedure: Costoclavicular Nerve Block; Procedure: suprascapular nerve block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first rescue analgesia after discharge from PACU.
Time to first rescue analgesia will be measured from the time of discharge from the Post-Anesthesia Care Unit (PACU) until the first administration of rescue analgesic medication for 24 hour due to postoperative pain. Numeric Rating Scale (NRS): Pain intensity was assessed using the 11-point Numeric Rating Scale (NRS), in which 0 = no pain and 10 = the worst pain imaginable.
Measured: From discharge from PACU until 24 hours postoperatively.
Secondary outcomes (8)
Postoperative Pain Score Using the Numeric Rating Scale
Postoperative pain intensity will be assessed from the end of surgery for 24 hours postoperatively using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate worse pain.
Measured: At predetermined time points after surgery at ( 2h,6h,12h,18h,24h) during the first 24 hours postoperatively.
Total Postoperative analgesic Consumption
The total amount of rescue analgesia consumed during the first 24 hours after surgery will be recorded.
Measured: First 24 hours postoperatively (one day).
Duration of sensory block
Duration of sensory block will be assessed as the time interval from completion of the nerve block to the first administration of rescue analgesia 24 hours postoperatively.
Measured: From completion of the nerve block until the first administration of rescue analgesia24 hours postoperatively.
Heart rate
Heart rate will be recorded at predefined perioperative time points to assess hemodynamic stability from baseline before surgery until end of surgery.
Measured: From baseline before the nerve block until the end of surgery.
Systolic blood pressure (SBP)
Systolic blood pressure will be recorded at baseline and at predefined intraoperative every 5 minutes and postoperative time points at (2h, 6h,12h,24h).
Measured: From baseline before anesthesia induction until 24 hours postoperatively.
Diastolic blood pressure (DBP)
Diastolic blood pressure will be recorded at baseline and at predefined intraoperative every 5 minutes and postoperative time points at (2h, 6h,12h,24h).
Measured: From baseline before anesthesia induction until 24 hours postoperatively.
Mean Arterial Pressure
Mean Arterial Pressure will be recorded at baseline and at predefined intraoperative every 5 minutes and postoperative time points at (2h, 6h,12h,24h).
Measured: From baseline before anesthesia induction until 24 hours postoperatively.
Incidence of Block-Related Adverse Events
The incidence of adverse events related to the regional anesthesia technique, including symptoms or complications associated with the nerve blocks, will be recorded.
Measured: From performance of the nerve blocks until 24 hours postoperatively.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Dec 2027 (estimated)
- Study completion30 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Shoulder ArthroscopyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to one of three parallel groups. Group A (control) will receive ultrasound-guided single-shot costoclavicular and suprascapular nerve blocks using bupivacaine with normal saline. Group B will receive the same nerve blocks with magnesium sulfate added to the local anesthetic solution. Group C will receive the same nerve blocks with normal saline, followed by intravenous administration of 150 mg magnesium sulfate diluted in 100 mL normal saline after completion of the nerve blocks. Participants will be followed postoperatively to assess analgesic outcomes, with time to first rescue analgesia as the primary outcome.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Shaban Abd Elbadea Khalifa, Assiut University
- Investigators
- Mohamed Mohamed Abdel Latif, professor, Principal investigator, Assiut University, Faculty of MedicineEman Ahmed Ismail, professor, Study director, Assiut University, Faculty of MedicineMohamed Talaat Mohamed, Lecturer, Study director, Assiut University, Faculty of MedicineAhmed Shaban Abd Elbadea Khalifa, Assistant lecturer, Study chair, Assiut University, Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07798115
- Sponsor's protocol ID
- SHOULDER-MAG-2026-01
- Acronym
- CCSS-Mg
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers because no plan for IPD sharing has been established. Study data will be used for the purposes of the current research and will be handled in accordance with institutional policies and applicable ethical and privacy requirements.
Publications
Pirotesak S, Fallah N, Alruqaie R, Rodelo K, Asenjo JF, Aliste J. Costoclavicular brachial plexus block for shoulder surgery: a narrative review. Korean J Anesthesiol. 2025 Dec;78(6):513-523. doi: 10.4097/kja.25422. Epub 2025 Aug 4.
PubMed 40755089Soleimanpour H, Imani F, Dolati S, Soleimanpour M, Shahsavarinia K. Management of pain using magnesium sulphate: a narrative review. Postgrad Med. 2022 Apr;134(3):260-266. doi: 10.1080/00325481.2022.2035092. Epub 2022 Feb 7.
PubMed 35086408Jo Y, Oh C, Lee WY, Chung HJ, Park J, Kim YH, Ko Y, Chung W, Hong B. Randomised comparison between superior trunk and costoclavicular blocks for arthroscopic shoulder surgery: A noninferiority study. Eur J Anaesthesiol. 2022 Oct 1;39(10):810-817. doi: 10.1097/EJA.0000000000001735. Epub 2022 Aug 17.
PubMed 35975762Nam YS, Jeong JJ, Han SH, Park SE, Lee SM, Kwon MJ, Ji JH, Kim KS. An anatomic and clinical study of the suprascapular and axillary nerve blocks for shoulder arthroscopy. J Shoulder Elbow Surg. 2011 Oct;20(7):1061-8. doi: 10.1016/j.jse.2011.04.022. Epub 2011 Aug 11.
PubMed 21839653Galluccio F, Fajardo Perez M, Yamak Altinpulluk E, Hou JD, Lin JA. Evaluation of Interfascial Plane and Pericapsular Nerve Blocks to the Shoulder Joint: A Preliminary Analysis of Shoulder Anterior Capsular Block. Pain Ther. 2021 Dec;10(2):1741-1754. doi: 10.1007/s40122-021-00326-0. Epub 2021 Oct 20.
PubMed 34669181Kay J, Memon M, Hu T, Simunovic N, Duong A, Paul J, Athwal G, Ayeni OR. Suprascapular Nerve Blockade for Postoperative Pain Control After Arthroscopic Shoulder Surgery: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2018 Dec 28;6(12):2325967118815859. doi: 10.1177/2325967118815859. eCollection 2018 Dec.
PubMed 30627589
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analgesic Effect of Additional Magnesium Sulfate to Standard Combined Costoclavicular-suprascapular Block in Shoulder Arthroscopy.
- ClinicalTrials.gov ID
- NCT07798115
- Acronym / sponsor ID
- CCSS-Mg / SHOULDER-MAG-2026-01
- Keywords
- Costoclavicular Block, Suprascapular Block, Magnesium Sulfate, Postoperative Pain, Shoulder Arthroscopy, Rescue Analgesia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 84 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Dec 2027 (estimated)
- Study completion
- 30 Mar 2028 (estimated)
- First posted
- 1 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate whether adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block improves postoperative pain control in patients undergoing shoulder arthroscopy. The study will compare pain management outcomes between patients receiving the nerve block with magnesium sulfate and those receiving the nerve block without magnesium sulfate. The main outcome will be the time to first rescue analgesia after surgery.
Detailed description
This randomized clinical trial will evaluate the analgesic effect of adding magnesium sulfate to a combined costoclavicular and suprascapular nerve block in patients undergoing shoulder arthroscopy. Shoulder arthroscopy can be associated with significant postoperative pain, and effective regional anesthesia may improve postoperative analgesia and reduce the need for rescue analgesics.
Eligible patients undergoing shoulder arthroscopy will be randomly assigned to receive either a combined costoclavicular and suprascapular nerve block with magnesium sulfate as an adjuvant or the same nerve block without magnesium sulfate. Standardized anesthetic and postoperative analgesic protocols will be applied to both groups.
The primary outcome will be the time to first rescue analgesia after surgery. Secondary outcomes will include postoperative pain scores and other relevant analgesic and safety outcomes during the postoperative observation period.
The study aims to determine whether the addition of magnesium sulfate can prolong the duration of analgesia and improve postoperative pain management following shoulder arthroscopy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
- Model description
- Participants will be randomly assigned to one of three parallel groups. Group A (control) will receive ultrasound-guided single-shot costoclavicular and suprascapular nerve blocks using bupivacaine with normal saline. Group B will receive the same nerve blocks with magnesium sulfate added to the local anesthetic solution. Group C will receive the same nerve blocks with normal saline, followed by intravenous administration of 150 mg magnesium sulfate diluted in 100 mL normal saline after completion of the nerve blocks. Participants will be followed postoperatively to assess analgesic outcomes, with time to first rescue analgesia as the primary outcome.
| Arm | Type | Receives |
|---|---|---|
| Costoclavicular-Suprascapular Block with Normal Saline | Experimental | Drug: Bupivacaine, Drug: Normal Saline (NS), Procedure: Costoclavicular Nerve Block, Procedure: suprascapular nerve blockParticipants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline. |
| Costoclavicular-Suprascapular Block with regional Magnesium Sulfate | Experimental | Drug: Bupivacaine, Drug: Magnesium sulfate (MgSO4), Procedure: Costoclavicular Nerve Block, Procedure: suprascapular nerve blockParticipants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of magnesium sulfate (150 mg), followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of magnesium sulfate (150 mg). |
| Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate | Experimental | Drug: Bupivacaine, Drug: Magnesium sulfate (MgSO4), Drug: Normal Saline (NS), Procedure: Costoclavicular Nerve Block, Procedure: suprascapular nerve blockParticipants will receive a single-shot ultrasound-guided costoclavicular brachial plexus block with 5 mL of 0.5% bupivacaine (25 mg) combined with 1.5 mL of 0.9% normal saline, followed by an ultrasound-guided suprascapular nerve block with 10 mL of 0.5% bupivacaine (50 mg) combined with 1.5 mL of 0.9% normal saline. Following the nerve blocks, participants will receive 150 mg of magnesium sulfate diluted in 100 mL of 0.9% normal saline administered intravenously. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age between 18-50 years
- American Society of Anesthesiologists (ASA) physical status I-II.
- Scheduled for elective outpatient shoulder arthroscopy.
- Ability to understand the study protocol and use the NRS scale.
Key exclusion criteria (9 listed)
- Refusal to participate.
- Known allergy or hypersensitivity to local anesthetics or magnesium sulphate.
- Coagulopathy or anticoagulant therapy contraindicating regional anesthesia.
- Local infection at the block site.
- Pre-existing peripheral neuropathy or neurologic deficit involving the operative limb.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bupivacaine"Bupivacaine 0.5% will be used as the local anesthetic for ultrasound-guided costoclavicular and suprascapular nerve blocks. A total of 25 mg (5 mL) will be administered for the costoclavicular nerve block and 50 mg (10 mL) for the suprascapular nerve block, for a total dose of 75 mg per participant." | Drug | Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate, Costoclavicular-Suprascapular Block with Normal Saline, Costoclavicular-Suprascapular Block with regional Magnesium Sulfate |
| Magnesium sulfate (MgSO4)"Magnesium sulfate 150 mg (1.5 mL) will be used as an adjuvant to bupivacaine in each ultrasound-guided nerve block. A total of 300 mg (3 mL) of magnesium sulfate will be administered per participant, with 150 mg added to the costoclavicular nerve block and 150 mg added to the suprascapular nerve block." | Drug | Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate, Costoclavicular-Suprascapular Block with regional Magnesium Sulfate |
| Normal Saline (NS)"Normal saline (0.9% sodium chloride) will be used as the control adjuvant, with 1.5 mL added to the local anesthetic solution for the costoclavicular nerve block and 1.5 mL added to the local anesthetic solution for the suprascapular nerve block, for a total volume of 3 mL per participant." | Drug | Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate, Costoclavicular-Suprascapular Block with Normal Saline |
| Costoclavicular Nerve Block"A single-shot ultrasound-guided costoclavicular nerve block will be performed using 5 mL of 0.5% bupivacaine (25 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group." | Procedure or surgery | Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate, Costoclavicular-Suprascapular Block with Normal Saline, Costoclavicular-Suprascapular Block with regional Magnesium Sulfate |
| suprascapular nerve block"A single-shot ultrasound-guided suprascapular nerve block will be performed using 10 mL of 0.5% bupivacaine (50 mg), with either 1.5 mL of magnesium sulfate (150 mg) or 1.5 mL of 0.9% normal saline, according to the assigned study group." | Procedure or surgery | Costoclavicular-Suprascapular Block with Intravenous Magnesium Sulfate, Costoclavicular-Suprascapular Block with Normal Saline, Costoclavicular-Suprascapular Block with regional Magnesium Sulfate |
Primary outcome
Time to first rescue analgesia after discharge from PACU.
Time frame: From discharge from PACU until 24 hours postoperatively.
Time to first rescue analgesia will be measured from the time of discharge from the Post-Anesthesia Care Unit (PACU) until the first administration of rescue analgesic medication for 24 hour due to postoperative pain. Numeric Rating Scale (NRS): Pain intensity was assessed using the 11-point Numeric Rating Scale (NRS), in which 0 = no pain and 10 = the worst pain imaginable.
8 secondary outcomes
Postoperative Pain Score Using the Numeric Rating Scale
Time frame: At predetermined time points after surgery at ( 2h,6h,12h,18h,24h) during the first 24 hours postoperatively.
Total Postoperative analgesic Consumption
Time frame: First 24 hours postoperatively (one day).
Duration of sensory block
Time frame: From completion of the nerve block until the first administration of rescue analgesia24 hours postoperatively.
Heart rate
Time frame: From baseline before the nerve block until the end of surgery.
Systolic blood pressure (SBP)
Time frame: From baseline before anesthesia induction until 24 hours postoperatively.
Diastolic blood pressure (DBP)
Time frame: From baseline before anesthesia induction until 24 hours postoperatively.
Mean Arterial Pressure
Time frame: From baseline before anesthesia induction until 24 hours postoperatively.
Incidence of Block-Related Adverse Events
Time frame: From performance of the nerve blocks until 24 hours postoperatively.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Background: PubMed 40755089Pirotesak S, Fallah N, Alruqaie R, Rodelo K, Asenjo JF, Aliste J. Costoclavicular brachial plexus block for shoulder surgery: a narrative review. Korean J Anesthesiol. 2025 Dec;78(6):513-523. doi: 10.4097/kja.25422. Epub 2025 Aug 4.
- Background: PubMed 35086408Soleimanpour H, Imani F, Dolati S, Soleimanpour M, Shahsavarinia K. Management of pain using magnesium sulphate: a narrative review. Postgrad Med. 2022 Apr;134(3):260-266. doi: 10.1080/00325481.2022.2035092. Epub 2022 Feb 7.
- Background: PubMed 35975762Jo Y, Oh C, Lee WY, Chung HJ, Park J, Kim YH, Ko Y, Chung W, Hong B. Randomised comparison between superior trunk and costoclavicular blocks for arthroscopic shoulder surgery: A noninferiority study. Eur J Anaesthesiol. 2022 Oct 1;39(10):810-817. doi: 10.1097/EJA.0000000000001735. Epub 2022 Aug 17.
- Background: PubMed 21839653Nam YS, Jeong JJ, Han SH, Park SE, Lee SM, Kwon MJ, Ji JH, Kim KS. An anatomic and clinical study of the suprascapular and axillary nerve blocks for shoulder arthroscopy. J Shoulder Elbow Surg. 2011 Oct;20(7):1061-8. doi: 10.1016/j.jse.2011.04.022. Epub 2011 Aug 11.
- Background: PubMed 34669181Galluccio F, Fajardo Perez M, Yamak Altinpulluk E, Hou JD, Lin JA. Evaluation of Interfascial Plane and Pericapsular Nerve Blocks to the Shoulder Joint: A Preliminary Analysis of Shoulder Anterior Capsular Block. Pain Ther. 2021 Dec;10(2):1741-1754. doi: 10.1007/s40122-021-00326-0. Epub 2021 Oct 20.
- Background: PubMed 30627589Kay J, Memon M, Hu T, Simunovic N, Duong A, Paul J, Athwal G, Ayeni OR. Suprascapular Nerve Blockade for Postoperative Pain Control After Arthroscopic Shoulder Surgery: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2018 Dec 28;6(12):2325967118815859. doi: 10.1177/2325967118815859. eCollection 2018 Dec.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers because no plan for IPD sharing has been established. Study data will be used for the purposes of the current research and will be handled in accordance with institutional policies and applicable ethical and privacy requirements.
Related trials for Shoulder Arthroscopy
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Recruiting
Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery
Postoperative Pain, Acute, Shoulder Pain
Not yet recruiting
ESP Versus SPSIP Block for Pain Relief After Shoulder Arthroscopy
Postoperative Pain
Active, not recruitingObservational study
Outcomes of Arthroscopic Dynamic Anterior Stabilization With and Without Remplissage
Anterior Shoulder Instability
RecruitingObservational study
SPSIP Block in Shoulder Artroscopy
Shoulder Arthroscopic Surgeries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed Mohamed Abdel Latif, professor principal investigator
Assiut University, Faculty of Medicine
Eman Ahmed Ismail, professor study director
Assiut University, Faculty of Medicine
Mohamed Talaat Mohamed, Lecturer study director
Assiut University, Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bupivacaine, Magnesium sulfate (MgSO4) and Normal Saline (NS) in people with Shoulder Arthroscopy and Postoperative Pain, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed Shaban Abd elbadea Khalifa, Assistant lecturer (+20 1143990130, ahmedshabann144@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first rescue analgesia after discharge from PACU. (time frame: From discharge from PACU until 24 hours postoperatively.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07798115, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.